For Canadian men over 40, few health concerns generate more anxiety than prostate symptoms. A weak urinary stream, frequent nighttime bathroom trips, or an elevated PSA test result can raise an immediate fear of prostate cancer. But the most common cause of these symptoms is something far less dangerous: benign prostatic hyperplasia, or BPH.
Understanding the difference between BPH and prostate cancer is one of the most important things a man can do for his health. They share some symptoms, but they are fundamentally different conditions with different causes, different risks, and very different outcomes.
What Is BPH?
Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland. The word "benign" is critical — BPH cells are not malignant, do not invade surrounding tissue, and cannot spread to other parts of the body. BPH is a normal part of male aging: the prostate gland, which surrounds the urethra just below the bladder, continues to grow throughout a man's life. When it grows large enough to compress the urethra, urinary symptoms develop.
BPH affects approximately 50% of men in their 50s and up to 90% of men in their 80s, making it one of the most prevalent conditions in aging men worldwide. It is not a precursor to prostate cancer and does not increase cancer risk.
What Is Prostate Cancer?
Prostate cancer is the uncontrolled growth of malignant cells within the prostate gland. It is the most commonly diagnosed cancer in Canadian men, with approximately 24,600 new cases diagnosed in Canada in 2023 according to the Canadian Cancer Society. Unlike BPH, prostate cancer has the potential to spread beyond the prostate to lymph nodes, bones, and other organs if left untreated.
Crucially, most prostate cancers grow slowly. Many men diagnosed with early-stage prostate cancer will never develop symptoms or require aggressive treatment — a phenomenon that has led to the widespread adoption of active surveillance protocols for low-risk disease.
↗ Canadian Cancer Society: Prostate Cancer StatisticsKey Differences at a Glance
| Feature | BPH | Prostate Cancer |
|---|---|---|
| Nature | Benign (non-cancerous) | Malignant |
| Can it spread? | No | Yes, if untreated |
| Prevalence in men 50+ | ~50% | ~15% lifetime risk |
| Urinary symptoms | Common, often prominent | Usually absent in early stages |
| PSA elevation | Mild to moderate | Can be elevated, sometimes markedly |
| Diagnosis | Symptom scores, flow studies, ultrasound | PSA, biopsy, MRI |
| Treatment | Watchful waiting, medication, surgery | Surveillance, radiation, surgery, hormone therapy |
| Risk to life | Minimal | Depends on stage and grade |
Overlapping Symptoms: Why Men Confuse the Two
Both BPH and prostate cancer involve the prostate gland, and both can produce urinary symptoms — but for different reasons. In BPH, the enlarged gland physically compresses the urethra. In prostate cancer, urinary symptoms typically only appear once the tumour has grown large enough to do the same, which is usually in more advanced disease.
Common urinary symptoms that can occur in both conditions:
- Weak or reduced urinary stream
- Frequent urination, especially at night (nocturia)
- Urgency — a sudden strong need to urinate
- Difficulty starting urination (hesitancy)
- Feeling of incomplete bladder emptying
Symptoms that are more specific to prostate cancer (particularly advanced disease):
- Blood in urine or semen (haematuria / haematospermia)
- Bone pain, particularly in the back, hips, or pelvis
- Unexplained weight loss
- Erectile dysfunction emerging alongside other symptoms
The Role of PSA Testing
Prostate-specific antigen (PSA) is a protein produced by both normal and abnormal prostate cells. Elevated PSA can indicate BPH, prostate inflammation (prostatitis), or prostate cancer. PSA alone cannot distinguish between these conditions — it is a signal that requires clinical interpretation, not a definitive diagnosis.
Both BPH and prostate cancer can elevate PSA. Men with large prostates due to BPH often have moderately elevated PSA levels that are entirely consistent with benign disease. A rising PSA over time, or a PSA density (PSA relative to prostate volume) above a certain threshold, is more clinically concerning than a single elevated reading.
↗ PubMed: Catalona et al. — PSA as a Prostate Cancer Screening ToolHow Each Is Diagnosed
BPH Diagnosis
BPH is typically diagnosed based on symptom assessment using validated tools such as the International Prostate Symptom Score (IPSS), combined with a digital rectal exam (DRE), PSA measurement, and sometimes transrectal ultrasound to measure prostate volume. Urodynamic studies may be used to assess bladder function and urinary flow rate.
Prostate Cancer Diagnosis
Prostate cancer cannot be definitively diagnosed without a biopsy. The diagnostic pathway typically involves elevated or rising PSA, followed by multiparametric MRI (mpMRI) of the prostate, and ultimately a targeted or systematic biopsy. The Gleason score and Grade Group system are used to characterize the aggressiveness of cancer cells identified on biopsy.
Can You Have Both BPH and Prostate Cancer?
Yes. BPH and prostate cancer are independent conditions that can and do coexist in the same gland. The presence of BPH does not protect against prostate cancer, and prostate cancer does not cause BPH. Men with symptomatic BPH should still undergo appropriate prostate cancer screening in accordance with their physician's recommendations and Canadian screening guidelines.
Screening Recommendations for Canadian Men
The Canadian Urological Association recommends that men discuss the benefits and limitations of PSA screening with their physician beginning at age 50 for average-risk men, and at age 40–45 for men with a family history of prostate cancer or those of African descent, who face higher risk. The decision to screen should be individualized and informed.
↗ Canadian Urological Association: Clinical GuidelinesThe Bottom Line
BPH and prostate cancer are not the same condition. BPH is extremely common, non-cancerous, and manageable. Prostate cancer is less common, potentially serious, but highly treatable when caught early. Urinary symptoms alone cannot distinguish between the two — a physician evaluation including PSA testing and physical examination is the only way to know.
If you are a Canadian man over 40 experiencing urinary symptoms, the most important step is to speak with your family physician. Do not assume your symptoms are benign, and do not assume they are cancer. Get assessed.